ENX-105

ENX-105
Clinical data
Other names	ENX105; Deuterated nemonapride enantiomer
Identifiers
	IUPAC name 5-chloro-2-methoxy-N-((2R,3R)-2-methyl-1-(phenylmethyl-d2)pyrrolidin-3-yl)-4-((methyl-d3)amino)benzamide;
CAS Number	2950168-16-6;
Chemical and physical data
Formula	C21H21ClD5N3O2
Molar mass	392.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C(N[C@H]1[C@@H](C)N(C(C2=CC=CC=C2)([2H])[2H])CC1)(=O)C3=C(OC)C=C(NC([2H])([2H])[2H])C(Cl)=C3;
	InChI InChI=InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)/t14-,18-/m1/s1/i2D3,13D2; Key:KRVOJOCLBAAKSJ-RUFGIDIBSA-N;

ENX-105 is an investigational new drug being developed by Engrail Therapeutics for the treatment of post-traumatic stress disorder (PTSD).^[2]^[3]^[4] It is currently in the preclinical stage, trailing behind a closely related Engrail compound, ENX-104,^[1] which is focused on depression and anhedonia.^[2]

The drug is described as a dopamine D₂ and D₃ receptor antagonist and serotonin 5-HT_1A and 5-HT_2A receptor agonist.^[1]^[3] In terms of its serotonin 5-HT_2A receptor agonism, it is said to not produce the head-twitch response in animals and hence to be putatively non-hallucinogenic.^[1]

As with ENX-104, ENX-105 is a deuterated enantiomer of nemonapride.^[1]

References

^ ^a ^b ^c ^d ^e "Corporate Summary" (PDF). Engrail Therapeutics, Inc. 2024.
^ ^a ^b Bayer M (19 March 2024). "Engrail closes $157M series B, fueled by investors' renewed interest in neuropsychiatry". Fierce Biotech.
^ ^a ^b "ENX-105". PatSnap.
^ WO 2023130117, Vadodaria K, Vanover K, Serrats J, Sudarsan V, Garvey D, "Preparation of deuterated pyrrolidin derivatives as modulators of dopamine and serotonin neurotransmission useful in treatment of diseases", assigned to Engrail Therapeutics, Inc.